Sherko Kümmel

20.8k citations

227 papers · 5.0k indexed · 1 hit paper · h-index 37

Impact in

Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology

Papers in

Cancer Research 121
- Breast Cancer Treatment Studies 107
- Cancer Genomics and Diagnostics 24
Oncology 133
- Cancer Treatment and Pharmacology 62
- HER2/EGFR in Cancer Research 46
- Cancer Immunotherapy and Biomarkers 25

Co-authors: Jens‐Uwe Blohmer Sibylle Loibl Gϋnter von Minckwitz Christian Jackisch Holger Cramer Holger Eidtmann Claus Hanusch Carsten Denkert
Journals: Journal of Clinical Oncology (37 papers)Annals of Oncology (23 papers)Cancer Research (16 papers)Breast Care (14 papers)European Journal of Cancer (8 papers)
Partner nations: Germany United States United Kingdom

In The Last Decade

Sherko Kümmel

219 papers receiving 4.8k citations

Hit Papers

align trajectories log scale

Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 2024 · 47 citations

Peers

Countries citing papers authored by Sherko Kümmel

Since Specialization

Citations

This map shows the geographic impact of Sherko Kümmel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherko Kümmel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherko Kümmel more than expected).

Fields of papers citing papers by Sherko Kümmel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherko Kümmel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherko Kümmel. The network helps show where Sherko Kümmel may publish in the future.

Co-authors

The 25 scholars most cited alongside Sherko Kümmel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sherko Kümmel Line = papers co-authored together Sherko Kümmel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 Annals of Oncology ·Lajos Pusztai, Carsten Denkert, Joyce O’Shaughnessy, Javier Cortés, Rebecca Dent, Heather L. McArthur, Sherko Kümmel, Jonas Bergh, Y.H. Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fátima Cardoso, Ying Zhu, Wilbur Pan, Konstantinos Tryfonidis, Peter Schmid Hit paper breakdown →	2024	47
2	Prognostic Implications of⁶⁸Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid Tumors Journal of Nuclear Medicine ·Masao Watanabe, Wolfgang P. Fendler, Hong Grafe, Nader Hirmas, Rainer Hamacher, Helena Lanzafame, Kim M. Pabst, Hubertus Hautzel, Clemens Aigner, Stefan Kasper, Bastian von Tresckow, Martin Stuschke, Sherko Kümmel, Céline Lugnier, Boris Hadaschik, Viktor Grünwald, Fadi Zarrad, Jens T. Siveke, Ken Herrmann, Manuel Weber	2024	9
3	LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study Annals of Oncology ·Peter Schmid, Javier Cortés, Rebecca Dent, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Carsten Denkert, Y.H. Park, Rina Hui, N. Harbeck, M. Takahashi, Theodoros Foukakis, M.A. Mouret Reynier, M.I.R. Ferreira, S-A. Im, Fátima Cardoso, Yu Ding, W. Pan, Konstantinos Tryfonidis, Joyce O’Shaughnessy	2023	20
4	The Partner Perspective on Autologous and Implant-Based Breast Reconstruction Aesthetic Plastic Surgery ·Maxi von Glinski, Nikla Holler, Sherko Kümmel, Christoph Wallner, Johannes Maximilian Wagner, Alexander Sogorski, Felix Reinkemeier, Mattea Reinisch, Marcus Lehnhardt, Björn Behr	2023	4
5	Efficacy and Safety of Auricular Acupuncture for the Treatment of Insomnia in Breast Cancer Survivors: A Randomized Controlled Trial Cancers ·Melanie Désirée Höxtermann, Katja Buner, Heidemarie Haller, Wiebke Kathrin Kohl-Heckl, Gustav Dobos, Mattea Reinisch, Sherko Kümmel, Holger Cramer, Petra Voiß	2021	35
6	Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial European Journal of Cancer ·Caroline Anna Peuker, Sarvenaz Yaghobramzi, Corinna Grunert, Luisa Keilholz, Enio Gjerga, Steffen Hennig, Sigrid Schaper, Il‐Kang Na, Ulrich Keller, Sara Y. Brucker, Thomas Decker, Peter A. Fasching, Tanja Fehm, Wolfgang Janni, Sherko Kümmel, Andreas Schneeweiß, Martin Schüler, Diana Lüftner, Antonia Busse	2021	19
7	Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin^®) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin) Anticancer Research ·Marcus Schmidt, Sherko Kümmel, Antonia Ruf-Doerdelmann, Andrea Distelrath, Jürgen Wacker, Sabine Schmatloch, SASKIA BUSCH-LILES, Kerstin Lüdtke-Heckenkamp	2021	5
8	Human Acellular Dermal Matrix (Epiflex®) in Immediate Implant-Based Breast Reconstruction after Skin- and Nipple-Sparing Mastectomy and Treatment of Capsular Fibrosis: Results of a Multicenter, Prospective, Observational NOGGO-AWOGyn Study Breast Care ·Lea Beier, Andreé Faridi, Corina Neumann, Stefan Paepke, Christine Mau, Maren Keller, H.‐J. Strittmatter, C Gerber-Schäfer, Lelia Bauer, Maria Margarete Karsten, Sherko Kümmel, Jens‐Uwe Blohmer	2020	4
9	Effects of an Integrative Mind-Body-Medicine Group Program on Breast Cancer Patients During Chemotherapy: An Observational Study Current Pharmaceutical Design ·Heidemarie Haller, Kyung‐Eun Choi, Silke Lange, Sherko Kümmel, Anna Paul, Holger Cramer, Gustav Dobos, Petra Voiß	2020	12
10	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial Journal of Clinical Oncology ·Aditya Bardia, Marina Parton, Sherko Kümmel, Laura García‐Estévez, Chiun‐Sheng Huang, Javier Cortés, Manuel Ruíz‐Borrego, Melinda L. Telli, Paloma Martín-Martorell, Rafael López‐López, J. Thaddeus Beck, Roohi Ismail‐Khan, Shin‐Cheh Chen, Sara A. Hurvitz, Ingrid A. Mayer, D. Carreon, Scott B. Cameron, Serena G. Liao, José Baselga, Sung‐Bae Kim	2018	55
11	Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor Clinical Cancer Research ·Sibylle Loibl, Karsten E. Weber, Jens Huober, Kristin Krappmann, Frederik Marmé, Christian Schem, Knut Engels, Berit M. Pfitzner, Sherko Kümmel, Jenny Furlanetto, Arndt Hartmann, Silvia Darb‐Esfahani, Volkmar Müller, Annette Staebler, Gϋnter von Minckwitz, Ralf Kronenwett, Carsten Denkert	2018	8
12	Using a New Marker Clip System in Breast Cancer: Tumark Vision® Clip - Feasibility Testing in Everyday Clinical Practice Breast Care ·Anna Rüland, Friederike Hagemann, Mattea Reinisch, Johannes Holtschmidt, Aylin Kümmel, Christine Dittmer-Grabowski, F. Stöblen, Horst Rotthaus, Volker Dreesmann, Jens‐Uwe Blohmer, Sherko Kümmel	2018	14
13	Autologous Lipotransfer - Daily Therapeutic Practice in Breast Cancer: An Intergroup Analysis Encompassing NOGGO, WSG, GBG, AWO Gyn and DGPRÄC Breast Care ·Aylin Kümmel, Sherko Kümmel, Jens‐Uwe Blohmer, Andreé Faridi, Ulrike Nitz, Sibylle Loibl, Uwe von Fritschen, Daniela Rezek, Friederike Hagemann, Johannes Holtschmidt, Suzan Botzenhardt, Mattea Reinisch	2018	1
14	Jumping Breast Phenomenon Following Subcutaneous Mastectomy: First Description and Grading of a Well-Known Breast Deformity Breast Care ·Sherko Kümmel, Aylin Kümmel, Friederike Hagemann, Anna Rüland, Christine Dittmer-Grabowski, Suzan Botzenhardt, Jens‐Uwe Blohmer, Mattea Reinisch	2018	7
15	Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre, Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive, High-Risk Breast Cancer Patients Breast Care ·Mattea Reinisch, Oleg Gluz, Beyhan Ataseven, Jens‐Uwe Blohmer, Marek Budner, Christine Dittmer-Grabowski, A. Kohls, J. Krocker, Aylin Kümmel, Friederike Hagemann, Anna Rüland, Alexander Traut, Sherko Kümmel	2018	2
16	Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis Acta Oncologica ·Heidemarie Haller, María M. Winkler, Petra Klose, Gustav Dobos, Sherko Kümmel, Holger Cramer	2017	194
17	Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) European Journal of Cancer ·Sherko Kümmel, Stefan Paepke, Jens Huober, Christian Schem, Michael Untch, Jens‐Uwe Blohmer, W. Eiermann, Bernd Gerber, Claus Hanusch, J. Hilfrich, Christian Jackisch, Andreas Schneeweiß, Carsten Denkert, Knut Engels, Peter Klare, Peter A. Fasching, Gϋnter von Minckwitz, Nicole Burchardi, Sibylle Loibl	2017	17
18	Definition of Concepts, Formation, Objectives and Prospects of Integrative Medicine AG mediaTUM (Technical University of Munich) ·Matthias Kalder, Tina Müller, David F. Fischer, A.B. Muller, Werner Bader, MW Beckmann, Cosima Brucker, CC Hack, Hanf, Annette Hasenburg, Anke Hein, Sebastian M. Jud, Marion Kiechle, Étienne Klein, Daniela Paepke, Andre-Robert Rotmann, Florian Schütz, G. Dobos, Petra Voiß, Sherko Kümmel	2015	1
19	Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Journal of Clinical Oncology ·Gϋnter von Minckwitz, Jens‐Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann, W. Eiermann, Bernd Gerber, Claus Hanusch, J. Hilfrich, Jens Huober, Christian Jackisch, Manfred Kaufmann, Sherko Kümmel, Stefan Paepke, Andreas Schneeweiß, Michael Untch, Dirk M. Zahm, Keyur Mehta, Sibylle Loibl	2013	265
20	Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: A phase II study Acta Oncologica ·Sherko Kümmel, Anke Thomas, Stefan Paepke, Marion Schwarz, Georg Heinrich, Andrea Wetzel, Dirk Elling, A. Kohls, W. Lichtenegger, Jens‐Uwe Blohmer	2005	5

About Sherko Kümmel

Sherko Kümmel is a scholar working on Cancer Research, Oncology, Complementary and alternative medicine, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 227 papers that have together received 5.0k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (107 papers), Cancer Treatment and Pharmacology (62 papers), Advanced Breast Cancer Therapies (48 papers), HER2/EGFR in Cancer Research (46 papers), Breast Lesions and Carcinomas (33 papers), Cancer Immunotherapy and Biomarkers (25 papers), Cancer Genomics and Diagnostics (24 papers) and Complementary and Alternative Medicine Studies (20 papers). The work is most often cited by research in Cancer Research (2.0k citations), Oncology (2.5k citations), Pathology and Forensic Medicine (910 citations), Radiology, Nuclear Medicine and Imaging (1.0k citations) and Hepatology (330 citations). Sherko Kümmel has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Jens‐Uwe Blohmer, Sibylle Loibl, Gϋnter von Minckwitz, Christian Jackisch, Holger Cramer, Holger Eidtmann, Claus Hanusch, Carsten Denkert, Thomas Fischer and Michael Untch. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Breast Care and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact